0001567619-18-005081.txt : 20181105 0001567619-18-005081.hdr.sgml : 20181105 20181105161427 ACCESSION NUMBER: 0001567619-18-005081 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181101 FILED AS OF DATE: 20181105 DATE AS OF CHANGE: 20181105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McCarthy Sean A. CENTRAL INDEX KEY: 0001654058 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37587 FILM NUMBER: 181160071 MAIL ADDRESS: STREET 1: 343 OYSTER POINT BLVD. STREET 2: SUITE 100 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CytomX Therapeutics, Inc. CENTRAL INDEX KEY: 0001501989 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273521219 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650.515.3185 MAIL ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc1.xml FORM 4 X0306 4 2018-11-01 0 0001501989 CytomX Therapeutics, Inc. CTMX 0001654058 McCarthy Sean A. 343 OYSTER POINT BLVD. SUITE 100 SOUTH SAN FRANCISCO CA 94080 1 1 0 0 President and CEO Common Stock 2018-11-01 4 M 0 5370 1.5749 A 87433 D Common Stock 2018-11-01 4 S 0 100 15.005 D 87333 D Common Stock 2018-11-01 4 S 0 5270 15 D 82063 D Common Stock 2018-11-02 4 M 0 1156 1.5749 A 83219 D Common Stock 2018-11-02 4 S 0 1156 15.007 D 82063 D Stock Option (Right to Buy) 1.5749 2018-11-01 4 M 0 5370 0 D 2025-02-08 Common Stock 5370 137227 D Stock Option (Right to Buy) 1.5749 2018-11-02 4 M 0 1156 0 D 2025-02-08 Common Stock 1156 136071 D The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. This option vests in 48 substantially equal monthly installments starting on the last day of January 2015. This transaction was executed in multiple trades in prices ranging from $15.00 to $15.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. /s/ Debanjan Ray, as Attorney-in-Fact for Sean A. McCarthy 2018-11-05